Cadrenal Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc. (CVKD), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on October 24, 2024. The filing discloses a capital raise event executed through the company's at-the-market (ATM) facility.
Key Financial Metrics
- Gross Proceeds: Approximately $5.1 million.
- Shares Sold: 391,243 shares of common stock.
- Weighted Average Price: $13.15 per share.
- Shares Outstanding: 1,496,771 shares as of October 23, 2024 (prior to the ATM sale completion).
- Revenue, Profit, Cash Flow, Margins, Debt: The filing text does not provide a clear value for these metrics as this is a current report focused on a specific equity transaction rather than a periodic financial statement.
Material Changes
The primary material change reported is the increase in the company's cash position due to the ATM sale and the corresponding increase in the number of shares outstanding. No comparative period data is provided in this filing to assess changes in operating performance.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing "forward-looking" statements subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The filing itself does not detail specific guidance, risks, or contingencies beyond the standard disclosure regarding the nature of forward-looking statements.
Investor Verification Checklist
- Verify the updated total share count post-transaction (1,496,771 + 391,243).
- Review the full text of the press release (Exhibit 99.1) for details on the intended use of the $5.1 million in proceeds.
- Confirm the remaining capacity under the ATM facility, if disclosed in the press release.
- Check for any underwriting agreements or selling shareholder agreements associated with the ATM facility.